Indore

Chordia Institute of Pharmacy is approved by All India Council of Technical Education (AICTE), Delhi and affiliated to Rajiv Gandhi proudyogiki Vishwavidalaya (M.P) and also approved from Pharmacy Council of India (PCI). The College was Established in 2007.

Post : Assistant Professor/ Lecturer

MIPS was established in 2007 as a dream of Late Shri P. Kharia as an education venture to impart education in Pharmacy Management education, & commerce streams . The courses launched were B.Pharm , M.Pharm.

Post : Associate Professor and Assistant professor

Ipca has been partnering healthcare globally in over 110 countries and in markets as diverse as Africa, Asia, Australia, Europe and the US. Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments. We are one of the world's largest manufacturers and suppliers of over a dozen APIs. These are produced right from the basic stage at manufacturing facilities endorsed by the world's most discerning drug regulatory authorities like US-FDA, UK-MHRA, EDQM-Europe, WHO-Geneva and many more. Ipca is a therapy leader in India for anti-malarials with a market-share of over 34% with a fast expanding presence in the international market as well.

1mg is India’s leading consumer health platform with over 3 Million downloads. It aspires to be the trusted health partner for all Indians and its mission is to make healthcare accessible, understandable and affordable for a billion Indians. It enables consumers to learn more about their medicines and also find more cost-effective substitutes. 1mg’s doctor platform aims to revolutionize how a consumer finds the right healthcare professional for his needs. It’s recently launched diagnostics service brings transparency and price-effectiveness to lab tests. 1mg is an initiative taken in the spirit of public service with a vision to empower Indian consumers and caregivers to select the most appropriate healthcare service at the best possible price.

Post : Pharmacist

IPCA now plus Rs.2700 Crores Company is global player with significant presence in over 110 countries with high brand equity in the domestic and international markets Our manufacturing facilities of bulk drugs at Ratlam have earned accreditations and approvals from the worlds most vigilant regulatory bodies.

Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with eight molecules in various stages of clinical development. The company has a significant presence in branded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business. The subsidiary also markets APIs to regulated and semi-regulated countries. Glenmark employs nearly 6000 people in over 80 countries. It has twelve manufacturing facilities in four countries and has five R&D centres.

Alembic Limited, with an established presence in the Indian pharma  industry has a proud, historical track record going back one hundred years. With a turnover in excess of Rs1000 crores today, Alembic Limited is one of India’s leading integrated pharmaceutical companies. We continue to enjoy leadership positions in antibiotics, anti-infective, anti-cough and also have significant worldwide presence in specialty therapeutic areas such as cardiology, neurology, diabetology, etc. We have also plans for expansion in Ophthalmic etc.

Cipla known for its innovative pharmaceutical products backed by latest in technology and creative marketing practices, is enjoying a commanding position among the top pharma companies in the country. Several specialised therapeutic divisions and promising new products have been launched and many more are in the pipeline.

The flagship company of the Piramal Group, Piramal Enterprises Ltd. (PEL), has business interests in Pharma, Information Management, and Financial Services verticals of the group.  Towards the late 80s, we shifted our focus from textile to pharmaceuticals. We chose to invest significantly in the domestic formulation development business, while other companies in the industry concentrated on international generics. Our efforts proved successful with a track record of approximately 23% revenue CAGR. In 2010, our strategy accomplished a sale of its domestic formulations business at an unprecedented value of ~9x sales and ~30x EBITDA.